Patent application number | Description | Published |
20110127381 | HARNESS WITH ADJUSTABLE BACK STRAP - A maintaining equipment with variable length side transverse strap segments in with the one side fastening strap, includes two pairs of saddle straps connected via saddle straps, to either the back transverse strap, back straps crossing the container backrest, or extension of the side transverse straps. The latter extends into a side fastening strap. A loop at a location locatable from the waist to the leg straps is run through by the side fastening strap or the side transverse strap. Strap tightening can occur at hooking or thereafter, allowing adjustment of the side transverse strap and the side fastening strap to maintain the container on the solo skydiver's back or maintain the passenger to the tandem pilot during freefall. Unlocking and/or loosening after canopy deployment elongates the side transverse strap with shortening of the side fastening strap allowing backward movement of the lower back and progression of the leg straps. | 06-02-2011 |
20140367514 | HOLDING CONTAINER FOR SHOCK ABSORBING SELF-DEPLOYABLE DEVICE - A device for absorbing impacts of a parachutist or airdropped package upon landing, which can equip a harness, and/or a skydiver or dropping pallet for performing the aircraft jump without any risk of interferences, allows, during the aircraft exit and free fall, to hold, neutralized in a reduced volume, an air-inflatable airbag, for deployment during the canopy descent. It includes a container back pad hooked to the harness and/or to the user or to the dropping pallet, which can be made removable by straps and bridles, in which an airbag is arranged such that its air scoop is closed by flaps locked by a cutaway cable. When the user exerts an action on the opening handle or when the parachute opens, the cable separates the flaps, allowing to unballast the airbag and open the air scoop to the air flow from the movement of the harness during the descent. | 12-18-2014 |
Patent application number | Description | Published |
20090230190 | METHOD AND APPARATUS FOR IDENTIFYING, AUTHENTICATING, TRACKING AND TRACING MANUFACTURED ITEMS - A method and apparatus for identifying manufactured items in containers, where each container is suitable for containing two or more units, and where the method comprises the steps of: associating each unit with a unique unit identifier, uniquely identifying each unit, allocating two or more units to be contained in each container, uniquely identifying each container, for each container, determining one or more ranges of unit identifiers of the two or more units allocated to the container, and storing, in a database, a container identifier for each container, each container identifier being coupled, in the database, to the one or more ranges of unit identifiers of the two or more units allocated to the container. There is also provided methods and apparatus for authenticating, tracking and tracing the units. | 09-17-2009 |
20140046852 | METHOD AND APPARATUS FOR MARKING MANUFACTURED ITEMS - A method and apparatus includes providing a cryptographic key, in an inactive state, to a point in a supply chain for manufactured items, providing the cryptographic key, in an active state, and an activation code for activating the cryptographic key, to a verification centre, and providing the activation code to the point in the supply chain in response to the point in the supply chain transmitting information relating to the received cryptographic key. The method includes generating, at the point in the supply chain, an identification (ID) code for each manufactured item, derived from the cryptographic key in the active state and a dynamic key generated for each batch of manufactured items. Including providing the dynamic key for each batch of manufactured items to the verification centre, marking each manufactured item with the ID code, and counting the actual or correct number of ID codes marked on the manufactured items. | 02-13-2014 |
Patent application number | Description | Published |
20110154046 | METHOD AND APPARATUS FOR STORAGE OF DATA FOR MANUFACTURED ITEMS - Exemplary embodiments are directed to a method and apparatus for storage of data for a batch of manufactured items. The method comprises defining, by a lower limit identifier and an upper limit identifier, a range of unique item identifiers for the batch, wherein each manufactured item in the batch is allocated a unique item identifier falling within the range. The number of unique item identifiers allocated to the manufactured items is smaller than the number of unique item identifiers in the range. The unique item identifiers allocated to the manufactured items are defined by the lower limit item identifier of the range, the upper limit item identifier of the range and an indication of those item identifiers in the range which are not allocated to a manufactured item. | 06-23-2011 |
20150310386 | METHOD AND APPARATUS FOR STORAGE OF DATA FOR MANUFACTURED ITEMS - Exemplary embodiments are directed to a method and apparatus for storing data for a batch of manufactured items. The method comprises defining in a processor, using a lower limit identifier and an upper limit identifier, a range of unique item identifiers for the batch, wherein each manufactured item in the batch is allocated a unique item identifier falling within the range. The item identifiers are stored in allocated storage space. If an upper limit identifier is specified for each time interval, an amount of storage specified for all manufactured items during a production time period is calculated as a sum of a first product and a second product, the first product being a product of a production time and a size allocated to each upper limit identifier, and the second product being a product of the production time, a total number of manufactured items, and a percentage of unused identifiers. | 10-29-2015 |
Patent application number | Description | Published |
20140293003 | METHOD FOR PROCESSING A STEREOSCOPIC IMAGE COMPRISING AN EMBEDDED OBJECT AND CORRESPONDING DEVICE - The invention relates to a method for processing a stereoscopic image comprising a first image L and a second image R, an object being embedded on the first and second images modifying the initial video content of pixels associated with the embedded object on the first and second images. In order to ensure coherence between the disparity associated with the embedded object and the video information associated with the pixels of first and second images, the method comprises steps for:
| 10-02-2014 |
20150015792 | FILTERING A DISPLACEMENT FIELD BETWEEN VIDEO FRAMES - The invention relates to a method for filtering a displacement field between a first image and a second image, a displacement field comprising for each pixel of the first (reference) image a displacement vector to the second image (current). The method comprises a first step of spatio-temporal filtering wherein a weighted sum of neighboring displacement vectors produces, for each pixel of the first image, a filtered displacement vector. The filtering step is remarkable in that a weight in the weighted sum is a trajectory weight, that is a trajectory weight is representative of a trajectory similarity. According to an advantageous characteristic, a trajectory associated to a pixel of the first image comprises a plurality of displacement vectors from the pixel to a plurality of images. According to another advantageous characteristic, a trajectory weight comprises a distance between a trajectory from the pixel and a trajectory from a neighboring pixel. The method also relates to a graphics processing unit and to computer-readable medium for implementing the weight filtering method. | 01-15-2015 |
20150035828 | METHOD FOR PROCESSING A CURRENT IMAGE OF AN IMAGE SEQUENCE, AND CORRESPONDING COMPUTER PROGRAM AND PROCESSING DEVICE - A method for processing a current image of an image sequence is disclosed. According to the invention, the method includes:
| 02-05-2015 |
Patent application number | Description | Published |
20090028888 | Cancer Antigen Mage-A9 and Uses Thereof - The present invention relates to the detection of MAGE-A9 in a biological sample and to the diagnosis, prevention and treatment of MAGE-A9-associated aberrant cell growth, through the targeting of the MAGE-A9 polypeptide and/or polynucleotide. Diagnosis is accomplished by examining or monitoring cells for perturbations in MAGE-A9 expression. Prevention and treatment are accomplished by administering to a subject MAGE-A9 as a protein or a fragment thereof or under form of a DNA expression vector, as well as by administering to a subject a MAGE-A9 gene product-binding agent. Compositions and commercial kits are also provided. | 01-29-2009 |
20100129824 | DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 05-27-2010 |
20110212449 | DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 09-01-2011 |
20120309001 | METHOD TO DETECT PROSTATE CANCER IN A SAMPLE - The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid. | 12-06-2012 |
20120315634 | DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 12-13-2012 |
20130149703 | "MARKERS FOR PROSTATE CANCER PROGRESSION" - Purpose. The relationship between inherited genetic variations in 5α-reductase type 1 (SRD5A1) and type 2 (SRD5A2) genes and the risk of biochemical recurrence after radical prostatectomy (RP) in prostate cancer (PCa) remains a fairly unexplored area of research. Patients and Methods. We studied 526 men with organ-confined and locally advanced PCa with a median follow-up time of 7.4 years. We investigated the effects of allelic variants of SRD5A1 and SRD5A2 genes and haplotype-tagging single nucleotide polymorphisms (htSNPs; n=19) on recurrence-free survival after RP using Kaplan-Meier plots, the log-rank test, and Cox proportional hazard models. Results. Upon adjusting for known prognostic clinical and pathological factors, eight htSNPs were shown to be independent predictors of recurrence. The SRD5A1 rs166050 polymorphism was associated with an increased recurrence risk of HR=1.83 (95% CI, 1.04-3.21; P=0.035), while the rs518673 in SRD5A1 was associated with a decreased risk (HR=0.59, 95% CI, 0.41-0.85; P=0.004). The SRD5A2 gene was strongly associated with the risk of relapse with six polymorphisms being positively associated with recurrence including the known SRD5A2 V89L (rs523349) (HR=2.14, 95% CI, 1.23-3.70; P=0.007) and a protective htSNP rs12470143 with a HR of 0.66, (95% CI, 0.46-0.95; P=0.023). By combining SRD5A1 (rs518673T) and SRD5A2 (rs12470143 A), the protective effect was shown to be additive with the maximum protection conferred by 3 or 4 alleles (HR=0.33, 95% CL 0.17-0.63; P=0.001). Conclusion. Germline polymorphisms in 5α-reductase genes are independent prognostic genetic biomarkers that predict PCa biochemical recurrence after radical prostatectomy and may represent useful molecular tools for a genotype-tailored clinical approach. | 06-13-2013 |
20130344487 | METHOD TO DETECT PROSTATE CANCER IN A SAMPLE - The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid. | 12-26-2013 |
20140087384 | DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 03-27-2014 |
20150218646 | METHODS, KITS AND COMPOSITIONS FOR PROVIDING A CLINICAL ASSESSMENT OF PROSTATE CANCER - The present invention relates to prostate cancer signatures which are useful for providing a clinical assessment of prostate cancer from a biological sample of a subject. By performing initial gene expression studies on urine samples from prostate cancer and non-prostate cancer subjects, and using the PCA3/PSA prostate cancer test as a performance benchmark, the present inventors have surprisingly discovered multiple signatures that are informative in urine-based prostate cancer tests, as well as in tissue-based tests. The signatures relate to combinations of at least two prostate cancer markers whose expression pattern in urine has been validated as being associated (either positively or negatively) with a clinical assessment of prostate cancer. The prostate cancer markers can be used in conjunction with bioinformatics approaches to generate a prostate cancer score, which correlates with a clinical assessment of prostate cancer. Methods, kits and compositions relating to the aforementioned signatures are also described. | 08-06-2015 |